APA (7th ed.) Citation

Veerapandiyan, A., Bourke, J., Soslow, J. H., Day, J. W., McDonald, C. M., Mendell, J. R., . . . Richardson, J. (2026). Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up. Cardiology & Therapy, 1. https://doi.org/10.1007/s40119-026-00457-5

Chicago Style (17th ed.) Citation

Veerapandiyan, Aravindhan, et al. "Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up." Cardiology & Therapy 2026: 1. https://doi.org/10.1007/s40119-026-00457-5.

MLA (9th ed.) Citation

Veerapandiyan, Aravindhan, et al. "Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up." Cardiology & Therapy, 2026, p. 1, https://doi.org/10.1007/s40119-026-00457-5.